IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma
Atezolizumab + bevacizumab▼ has been approved globally for the treatment of patients with unresectable HCC who have not received prior systemic therapy. With a median follow-up of 8.6 mo, statistically significant and clinically meaningful improvements were observed with atezolizumab + bevacizumab▼ vs sorafenib. Updated efficacy data for IMbrave150 with twelve months of additional follow-up are presented.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.